- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Mediwound Ltd(MDWD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MDWD
11/20/2026: MDWD (1-star) is currently NOT-A-BUY. Pass it for now.
MediWound Ltd. is a commercial-stage biopharmaceutical stock focused on developing non-surgical enzymatic therapies for tissue repair. The company's primary operational strength is its FDA-approved flagship product, NexoBrid, which enjoys growing clinical adoption in severe burn care. Its key investment appeal lies in the late-stage development of EscharEx, offering asymmetric growth upside into the chronic wound market. However, investors face risks from ongoing net losses, capital dilution needs, and execution hurdles in clinical trials. The stock suits growth-oriented investors willing to tolerate biotech volatility while monitoring upcoming clinical trial readouts and commercial adoption trends.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | MediWound offers significant percentage upside tied to late-stage clinical trials and expanding adoption of its novel enzymatic therapies. |
| Momentum investor | Strong fit while signal remains positive | Momentum appeal depends closely on positive clinical catalysts, regulatory news updates, and favorable short-term price breakouts. |
| Value investor | Weak fit | The company is currently pre-profitable with high operational expenses, making traditional valuation models less applicable. |
| Dividend investor | Weak fit | MediWound does not pay dividends, retaining all capital for drug development and commercial growth. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology investing entails high stock volatility, regulatory risk, and continuous capital requirements. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results, regulatory updates, and equity offerings frequently cause sharp swings in share price. |
| Valuation risk | Medium / high | Valuation relies heavily on speculative future cash flows from pipeline assets rather than current earnings. |
| Competition risk (alternative wound care treatments) | Medium | Established surgical methods and competing debridement products challenge rapid market penetration. |
| Business quality | Medium | Proprietary biologic assets provide a defensible scientific moat, though commercial scale is still developing. |
| Dividend income | Low / none | No cash dividends are distributed to shareholders. |
| Execution risk | High | Success depends heavily on meeting clinical trial milestones, securing regulatory approvals, and scaling manufacturing. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 195.56M USD | Price to earnings Ratio - | 1Y Target Price 29.67 |
Price to earnings Ratio - | 1Y Target Price 29.67 | ||
Volume (30-day avg) 153.7K shares | Beta 0.04 | 52 Weeks Range 11.80 - 19.70 | Updated Date 11/21/2026 |
52 Weeks Range 11.80 - 19.70 | Updated Date 11/21/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.59 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Biotechnology
- BUY participation
- 43.2%
- Active BUY / eligible
- 19 / 44
- 30-Day BUY Count Change
- +12
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -33.58% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercial Product Sales (NexoBrid) | Revenues generated from the sale of NexoBrid to hospitals, burn centers, and commercial partners like Vericel. | This is the core current revenue driver supporting commercial validation. |
| Collaborations and Grants | Funding and milestone payments from government agencies or commercial partners supporting clinical development. | Provides non-dilutive capital and validates the platform's clinical utility. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 34.97 | Enterprise Value 176.16M | Price to Sales(TTM) 19.54 |
Enterprise Value 176.16M | Price to Sales(TTM) 19.54 | ||
Enterprise Value to Revenue 17.6 | Enterprise Value to EBITDA -6.32 | Shares Outstanding 14.39M | Shares Floating 8.87M |
Shares Outstanding 14.39M | Shares Floating 8.87M | ||
Percent Insiders 15.47 | Percent Institutions 54.33 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

